Ovidrel Dosage/Direction for Use

Treatment with Ovidrel should be performed under the supervision of a physician experienced in the treatment of fertility problems.
Posology: The maximum dose is 250 micrograms.
The following dosing regimen should be used: Women undergoing superovulation prior to assist reproductive technologies (ART) such as in vitro fertilization (IVF): One pre-filled syringe or prefilled pen of Ovidrel (250 micrograms) is administered 24 to 48 hours after the last administration of a follicle stimulating hormone (FSH) or human menopausal gonadotropin (hMG) preparation, i.e. when optimal stimulation of follicular growth is achieved.
Anovulatory or oligo-ovulatory women: One pre-filled syringe or prefilled pen of Ovidrel (250 micrograms) is administered 24 to 48 hours after optimal stimulation of follicular growth is achieved. The patient is recommended to have coitus on the day of, and the day after, Ovidrel injection.
Special populations: Renal or hepatic impairment: Safety, efficacy and pharmacokinetics of Ovidrel in patients with renal or hepatic impairment have not been established.
Paediatric population: There is no relevant use of Ovidrel in the paediatric population.
Method of administration: For subcutaneous use. Self-administration of Ovidrel should only be performed by patients who are adequately trained and have access to expert advice.
Ovidrel is for single use only.